Larimar Therapeutics, Inc. (LRMR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.76+8.66%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · LRMR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
In June, Larimar submitted the first module of its rolling BLA submission seeking accelerated approval.
Stated in 2 of 2 supplied quarters. Management reported: “In June, Larimar submitted the first module of its rolling BLA submission seeking accelerated approval.” “• Rolling BLA Submission: Completion expected 2H 2026 of submission seeking accelerated approval.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“In June, Larimar submitted the first module of its rolling BLA submission seeking accelerated approval.”
“Pending FDA feedback, Larimar is planning to seek accelerated approval in a rolling BLA with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the…”
Upcoming Milestones • Global Confirmatory Phase 3 Study: Dosing of first patient expected Q3 2026.
Stated in 2 of 2 supplied quarters. Management reported: “Upcoming Milestones • Global Confirmatory Phase 3 Study: Dosing of first patient expected Q3 2026.” “We are also on track to initiate dosing in our global confirmatory study this quarter.”
“Upcoming Milestones • Global Confirmatory Phase 3 Study: Dosing of first patient expected Q3 2026.”
“• Global Confirmatory Phase 3 Study: Plan to initiate dosing of first patient mid-2026.”
• Launch Timing: Targeting mid-2027 launch, if approved.
Stated in 2 of 2 supplied quarters. Management reported: “• Launch Timing: Targeting mid-2027 launch, if approved.” “The increase in general and administrative expenses primarily related to the acceleration of commercial activities as we prepare for the planned mid-2027 launch of nomlabofusp, if approved.”
“• Launch Timing: Targeting mid-2027 launch, if approved.”
“Targeting first half 2027 launch, if approved.”
The Company projects its cash runway into the third quarter of 2027.
Stated in 2 of 2 supplied quarters. Management reported: “The Company projects its cash runway into the third quarter of 2027.” “Second Quarter 2026 Financial Results As of June 30, 2026, the Company had cash, cash equivalents and marketable securities totaling $156.3 million.”
“The Company projects its cash runway into the third quarter of 2027.”
“First Quarter 2026 Financial Results As of March 31, 2026, the Company had cash, cash equivalents and marketable securities totaling $200.4 million.”
Provide topline data from the ongoing open-label study to support BLA submission and demonstrate nomlabofusp's safety and efficacy.
Over the trailing year it converted 1.05x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-04.